Eli Lilly | LLY - Net Income


Eli Lilly reported $7.4B in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Abbott USD 1.08B 699M Mar/2026
ALKERMES USD -66.48M 115.82M Mar/2026
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Baxter International USD -15M 1.11B Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Drreddys Laboratories INR 2.21B 9.89B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
J&J USD 5.53B 299M Jun/2026
Medtronic USD 1.24B 100M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novo Nordisk DKK 26.89B 388M Dec/2025
Perrigo USD -398.6M 1.02B Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Phibro Animal Health USD 27.46M 932K Dec/2025
Prestige Brands USD 46.7M 22.44M Dec/2025
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Sanofi EUR 1.61B 2.42B Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Zoetis USD 601M 2M Mar/2026